Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular OutcomesRohan Khera, Patrick B. Ryan, Tara V. Anand et al.|Journal of the American College of Cardiology|2024Cited by 33
Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort studyErica A. Voss, Rohit Vashisht, Kevin Haynes et al.|EClinicalMedicine|2023Cited by 27
Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DMRohan Khera, Marc A. Suchard, Michael B. Cook et al.|BMJ Medicine|2023Cited by 27
Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDISKristin Kostka, Nicole G. Weiskopf, Neus Valveny et al.|Clinical Epidemiology|2022Cited by 26
Supporting Pharmacovigilance Signal Validation and Prioritization with Analyses of Routinely Collected Health Data: Lessons Learned from an EHDEN Network StudyOskar Gauffin, G. Niklas Norén, Milan Lazarević et al.|Drug Safety|2023Cited by 19